• Eva Sten, Per Stahl Skov, Sven B Andersen, Anna Maria Torp, Annette Olesen, Ulla Bindslev-Jensen, Lars K Poulsen, and Carsten Bindslev-Jensen.
• Allergy Clinic, 7542, National University Hospital, Blegdamsvej 9, 2100 Copenhagen Ø, Denmark. E.STEN@RH.DK
• APMIS. 2004 Jan 1; 112 (1): 21-8.

AbstractA large proportion of soybean cultivars grown in the USA are now genetically modified varieties and concern has been raised about the safety of these products for consumers. A study of the impact on allergenic potency in soybeans, comparable except for the newly introduced gene (CP4 EPSPS), was performed using soybean-sensitized patients. The allergenicity of 18 different (10 GM and 8 WT) soybean extracts was examined blindly by the following three methods: A) Sera from patients with specific IgE against soybean were used to determine concentrations inducing 50% RAST inhibition; B) Histamine release induced by the extracts was examined using blood from sensitized patients; C) SPT was performed on sensitized patients with all 18 extracts. All three methods showed variations in the allergenic potency between the individual extracts but allergenic potential was not affected by presence of the transgene. By using standard in vitro methods and SPT for determination of allergenicity we were not able to detect any significant difference in the allergenic potency between GM and WT soybeans.

18 keywords...

hide…